research EFFECT OF "AMINOPTERIN" ON EPITHELIAL TISSUES
Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Azelaic Acid in the Treatment of Acne in Adult Females: Case Reports
Azelaic Acid is effective and safe for treating adult female acne, with few side effects.
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research Flurandrenolide
research Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern
Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
research Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review
Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
research Azelaic Acid in Dermatology: A Review of Its Mechanism of Action
Azelaic acid helps with skin pigmentation issues, but its full effects are not completely understood.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata
Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.
research The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications
Azelaic acid treats acne, rosacea, and hyperpigmentation with minimal side effects.
research Bimatoprost
Bimatoprost may help treat hair loss from alopecia areata.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research 708 Promotion of hair growth in alopecia areata by topical treatment of HDAC inhibitors
HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research Treatment of alopecia areata with squaric acid dibutylester
Squaric acid dibutylester effectively treats alopecia areata.
research Azathiopine for the Treatment of Extensive Forms of Alopecia Areata: A Systematic Review
Azathioprine may help treat severe alopecia areata, but more research is needed.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Bimatoprost solution 0·03% topical application to the eyelid margin for the treatment of eyelash hypotrichosis
Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
research Topical Bimatoprost (0.03%) Versus Topical Mometasone Furoate (0.1%) in Treatment of Alopecia Areata
Mometasone furoate cream was more effective than bimatoprost solution for treating hair loss from Alopecia Areata.
research Alefacept for Alopecia Areata
Alefacept showed some effectiveness for alopecia areata but needs more research.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.